SUPPLEMENTARY MATERIAL

Antifungal Activity of Phenolic Monoterpenes and Structure-related Compounds against Plant Pathogenic Fungi

Kaibo Wang¹, Shanshan Jiang¹, Te Pu, Liming Fan, Fawu Su*, Min Ye*

State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan Agricultural University, Kunming 650201, China

*Corresponding author. Email: su_faw@126.com; e-mail: yeminpc@126.com

The aim of this work is to explore the possibility of using the phenolic monoterpenes (PMs) as leading compounds with antifungal activity against plant disease. The *in vitro* antifungal activities of carvacrol and thymol against 7 kinds of plant pathogenic fungi were evaluated on mycelium growth rate method, and the results showed that carvacrol and thymol exhibited broad spectrum antifungal activity. Structure requirement for the antifungal activity of PMs was also investigated. The preliminary conclusion was that phenolic hydroxyl and monoterpene were basic structures for the antifungal activity of PMs, and the position of phenolic hydroxyl showed less effect. Ester derivatives of carvacrol and thymol were more effective than carvacrol and thymol against plant pathogenic fungi. We suggested that carvacrol, thymol and their ester derivatives could potentially be used as new fungicide leading compounds.

¹ These authors contributed equally to this work.

Characterization and Spectroscopy data for synthetic compounds

5-isopropyl-2-methylphenyl acetate (**1a**). Colorless oil. ¹H-NMR (500 MHz, CDCl₃): 7.13 (d, J = 7.8 Hz, 1 arom. H), 7.01 (d, J = 7.7 Hz, 1 arom. H), 6.86 (s, 1 arom. H), 2.87 (m, H-C(8)), 2.30 (s, CH₃(13)), 2.13 (s, CH₃(7)), 1.22 (d, J = 6.9 Hz, CH₃(9, 10)) . ¹³C-NMR (125 MHz, CDCl₃): 169.3 (C(12); 149.3 (C(5)); 148.1 (C(3)); 130.9 (C(1)); 127.2 (C(6)); 124.2(C(2)); 119.8 (C(4)); 33.6 (C(8)); 23.9 (C(9, 10)); 20.8 (C(13)) 15.8 (C(7)). HR-ESI-MS: 193.1226 ([M+H]⁺, C₁₂H₁₇O₂⁺; calc. 193.1223).

2-ethoxy-4-isopropyl-1-methylbenzene (**2a**). Colorless oil. ¹H-NMR (500 MHz, CDCl₃): 7.04 (d, J = 7.3 Hz, 1 arom. H), 6.71 (d, J = 7.4 Hz, 1 arom. H), 6.68 (s, 1 arom. H), 4.03 (q, J = 13.7, 6.8 Hz, CH₂(12)), 2.84 (m, H-C(8)), 2.18 (s, CH₃(7)), 1.41 (t, J = 6.9 Hz, CH₃(13)), 1.23 (d, J = 6.9 Hz, CH₃(9,10)). ¹³C-NMR (125 MHz, CDCl₃): 157.2 (C(5)); 147.9 (C(3)); 130.4 (C(1)); 124.2 (C(6)); 118.0 (C(2)); 109.7 (C(4)); 63.5 (C(12)); 34.2 (C(8)); 24.2 (C(9, 10)); 15.9 (C(7)); 15.1 (C(13)). HR-ESI-MS: 179.1429 ([M+H]⁺, C₁₂H₁₉O⁺; calc. 179.1430).

Synthesis of 2-isopropyl-5-methylphenyl acetate (**1b**). Colorless oil. ¹H-NMR (500 MHz, CDCl₃): 7.19 (d, J = 7.9 Hz, 1 arom. H), 7.02 (d, J = 7.9 Hz, 1 arom. H), 6.80 (s, 1 arom. H), 2.97 (m, H-C(7)), 2.31 (s, CH₃(8, 11)), 1.19 (d, J = 6.9 Hz, CH₃(13, 14)). ¹³C-NMR (125 MHz, CDCl₃): 169.8 (C(10); 147.9 (C(5)); 137.0 (C(6)); 136.6 (C(3)); 127.2 (C(2)); 126.5(C(1)); 122.8 (C(4)); 27.2 (C(7)); 23.1 (C(13, 14)); 21.0 (C(8)); 20.8 (C(11)). HR-ESI-MS: 193.1227 ([M+H]⁺, C₁₂H₁₇O₂⁺; calc. 193.1223).

Synthesis of 4-ethoxy-2-isopropyl-1-methylbenzene (**2b**). Colorless oil. ¹H-NMR (500 MHz, CDCl₃): 7.08 (d, J = 7.6 Hz, 1 arom. H), 6.72 (d, J = 7.6 Hz, 1 arom. H), 6.65 (s, 1 arom. H), 4.01 (q, J = 6.9 Hz, CH₂(10)), 3.29 (m, H-C(7)), 2.31 (s, CH₃(8)), 1.41 (t, J = 6.9 Hz, CH₃(11)), 1.20 (d, J = 6.9 Hz, CH₃(12, 13)). ¹³C-NMR (125 MHz, CDCl₃): 156.1 (C(5)); 136.2 (C(3)); 134.2 (C(6)); 125.9 (C(1)); 121.0 (C(2)); 112.5 (C(4)); 63.6 (C(10)); 26.7 (C(7)); 22.8 (C(12, 13)); 21.4 (C(8)); 15.1 (C(11)). HR-ESI-MS: 179.1438 ([M+H]⁺, C₁₂H₁₉O⁺; calc. 179.1430).





¹H NMR (500 MHz, CDCl₃) δ 7.04 (d, *J* = 7.3 Hz, 1 arom. H), 6.71 (d, *J* = 7.4 Hz, 1 arom. H), 6.68 (s, 1 arom. H), 4.03 (q, *J* = 13.7, 6.8 Hz, CH₂(12)), 2.84 (m, H-C(8)), 2.18 (s, CH₃(7)), 1.41 (t, *J* = 6.9 Hz, CH₃(13)), 1.23 (d, *J* = 6.9 Hz, CH₃(9,10)).



Figure S2.¹³C NMR of compound 2a

¹³C NMR (125 MHz, CDCl₃): 157.2 (C(5)); 147.9 (C(3)); 130.4 (C(1)); 124.2 (C(6)); 118.0 (C(2)); 109.7 (C(4)); 63.5 (C(12)); 34.2 (C(8)); 24.2 (C(C9, C10)); 15.9 (C(7)); 15.1 (C(13))

Figure S3. HR-ESI-MS of compound 2a

08 #89 RT: 5.96 AV: 1 NL: 1.13E4 F: FTMS + c ESI Full ms [170.00-350.00]



Figure S4. ¹H NMR of compound **1a**



¹H NMR (500 MHz, CDCl₃) δ 7.13 (d, J = 7.8 Hz, 1 arom. H), 7.01 (d, J = 7.7 Hz, 1 arom. H), 6.86 (s, 1 arom. H), 2.87 (m, H-C(8)), 2.30 (s, CH₃(13)), 2.13 (s, CH₃(7)), 1.22 (d, J = 6.9 Hz, CH₃(9, 10)).



Figure S5.¹³C NMR of compound **1a**

¹³C NMR (125 MHz, CDCl₃): 169.3 (C(12); 149.3 (C(5)); 148.1 (C(3)); 130.9 (C(1)); 127.2 (C(6)); 124.2(C(2)); 119.8 (C(4)); 33.6 (C(8)); 23.9 (C(C9, C10)); 20.8 (C(13)) 15.8 (C(7))

09 #87	RT: 5.82 AV: 1 NL: 3.56E3								
P: PIMS	+ c ESI Full ms [170.00-350.00]		193.1226						
			C 12 H 17 O2 = 193.122	3					
100 E									
0F -									
- ²⁰ T									
E.o.									
85									
80-									
3									
75-									
70-									
65									
⁶⁰ -									
100									
50-									
45									
40									
35									
30-									
201									
203									
~ 1									
15-									
10									
5-									
1									
0-4	103 1215	193 1220	193 1225	193 1230	193 1235	193 1240	193 1245	193 1250	193 1255
	100.1210	100.1440	100.1220	155.1255	m/z	100.1240	100.1240	100.1200	100.1200



Figure S7. ¹H NMR of compound **2b**

¹H NMR (500 MHz, CDCl₃) δ 7.08 (d, *J* = 7.6 Hz, 1 arom. H), 6.72 (d, *J* = 7.6 Hz, 1 arom. H), 6.65 (s, 1 arom. H), 4.01 (q, *J* = 6.9 Hz, CH₂(10)), 3.29 (m, H-C(7)), 2.31 (s, CH₃(8)), 1.41 (t, *J* = 6.9 Hz, CH₃(11)), 1.20 (d, *J* = 6.9 Hz, CH₃(12, 13)).





¹³C NMR (125 MHz, CDCl₃): 156.1 (C(5)); 136.2 (C(3)); 134.2 (C(6)); 125.9 (C(1)); 121.0 (C(2)); 112.5 (C(4)); 63.6 (C(10)); 26.7 (C(7)); 22.8 (C(C12, C13)); 21.4 (C(8)); 15.1 (C(11))

Figure S9. HR-ESI-MS of compound 2b







¹H NMR (500 MHz, CDCl₃) δ 7.19 (d, J = 7.9 Hz, 1 arom. H), 7.02 (d, J = 7.9 Hz, 1 arom. H), 6.80 (s, 1 arom. H), 2.97 (m, H-C(7)), 2.31 (s, CH₃(8, 11)), 1.19 (d, J = 6.9 Hz, CH₃(13, 14)).



Figure S11.¹³C NMR of compound **1b**

¹³C NMR (125 MHz, CDCl₃): 169.8 (C(10); 147.9 (C(5)); 137.0 (C(6)); 136.6 (C(3)); 127.2 (C(2)); 126.5(C(1)); 122.8 (C(4)); 27.2 (C(7)); 23.1 (C(C13, C14)); 21.0 (C(8)); 20.8 (C(11))

Figure S12. HR-ESI-MS of compound 1b

